# A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma

> **NCT04983810** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Cyclacel Pharmaceuticals, Inc.** · enrollment: 330 (estimated)

## Conditions studied

- Solid Tumor, Adult
- Lymphoma

## Interventions

- **DRUG:** Fadraciclib

## Key facts

- **NCT ID:** NCT04983810
- **Lead sponsor:** Cyclacel Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-12
- **Primary completion:** 2025-04-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 330 (ESTIMATED)
- **Last updated:** 2024-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04983810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04983810, "A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04983810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*